Literature DB >> 19639220

Molecular pathways supporting the proliferation staging of malignant melanoma (review).

Pascale Quatresooz1, Gerald E Pierard, Claudine Pierard-Franchimont.   

Abstract

The clinical diagnosis of cutaneous melanoma always calls for histological confirmation. In addition to the recognition of the classic aspects of the neoplasm, immunohistochemistry is determinant, in particular in the assessment of the size of the replicative compartment. Generally, the proliferation rate is indicative of the neoplastic progression and is related to the clinical growth rate of the neoplasm. It allows to distinguish high risk melanomas showing a high growth rate from those of lower malignancy associated with a restricted growth rate. In melanoma, the recruitment and progression of neoplastic cells in the cell cycle of proliferation have lost some of their controls that are normally processed by a series of key regulatory molecules. In addition, the apoptotic pathway counteracting any hyperproliferative activity is released of the dependency of specific regulated molecular mechanisms. This review summarizes the current knowledge on key molecular components involved in the deregulation of the growth fraction, cell proliferation and apoptosis in melanocytic neoplasms. The implication of cyclins and of the mitogen-activated protein kinase pathways are scrutinized. The involvement of neoplastic stem cells in the metastatic process is also discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639220     DOI: 10.3892/ijmm_00000232

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  11 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma.

Authors:  Orazio Vittorio; Giuseppe Cirillo; Francesca Iemma; Giovanni Di Turi; Emanuela Jacchetti; Michele Curcio; Serena Barbuti; Niccola Funel; Ortensia Ilaria Parisi; Francesco Puoci; Nevio Picci
Journal:  Pharm Res       Date:  2012-05-24       Impact factor: 4.200

3.  'Malignant melanoma microecosystem': Immunohistopathological insights into the stromal cell phenotype.

Authors:  Pascale Quatresooz; Marie-Annick Reginster; Gérald E Piérard
Journal:  Exp Ther Med       Date:  2011-02-28       Impact factor: 2.447

4.  Molecular dermatopathology in malignant melanoma.

Authors:  Marie-Annick Reginster; Claudine Pierard-Franchimont; Gérald E Piérard; Pascale Quatresooz
Journal:  Dermatol Res Pract       Date:  2011-10-20

5.  Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?

Authors:  Gérald E Piérard; François Aubin; Philippe Humbert
Journal:  Dermatol Res Pract       Date:  2011-10-23

6.  Thigmotropism of malignant melanoma cells.

Authors:  Pascale Quatresooz; Claudine Piérard-Franchimont; Fanchon Noël; Gérald E Piérard
Journal:  Dermatol Res Pract       Date:  2011-11-17

7.  Smouldering malignant melanoma and metastatic dormancy: an update and review.

Authors:  Gérald E Piérard; Claudine Piérard-Franchimont; Marie-Annick Reginster; Pascale Quatresooz
Journal:  Dermatol Res Pract       Date:  2011-11-02

8.  Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.

Authors:  G E Piérard
Journal:  ISRN Dermatol       Date:  2012-01-11

9.  Malignant melanoma and its stromal nonimmune microecosystem.

Authors:  Gérald E Piérard; Claudine Piérard-Franchimont; Philippe Delvenne
Journal:  J Oncol       Date:  2012-06-28       Impact factor: 4.375

10.  HOX Gene Aberrant Expression in Skin Melanoma: A Review.

Authors:  Gérald E Piérard; Claudine Piérard-Franchimont
Journal:  J Skin Cancer       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.